1 – 5 of 5
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
(
- Contribution to journal › Article
-
Mark
The european hematology association roadmap for european hematology research : A consensus document
(
- Contribution to journal › Article
- 2010
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article
-
Mark
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
(
- Contribution to journal › Article